National Cancer Institute pediatric preclinical testing program: Model description for in vitro cytotoxicity testing
- 4 October 2010
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 56 (2), 239-249
- https://doi.org/10.1002/pbc.22801
Abstract
Background The National Cancer Institute (NCI) has established the Pediatric Preclinical Testing Program (PPTP) for testing drugs against in vitro and in vivo childhood cancer models to aid in the prioritization of drugs considered for early phase pediatric clinical trials. Procedures In vitro cytotoxicity testing employs a semi‐automated fluorescence‐based digital imaging cytotoxicity assay (DIMSCAN) that has a 4‐log dynamic range of detection. Curve fitting of the fractional survival data of the cell lines in response to various concentrations of the agents was used to calculate relative IC50, absolute IC50, and Ymin values. The panel of 23 pediatric cancer cell lines included leukemia (n = 6), lymphoma (n = 2), rhabdomyosarcoma (n = 4), brain tumors (n = 3), Ewing family of tumors (EFT, n = 4), and neuroblastoma (n = 4). The doubling times obtained using DIMSCAN were incorporated into data analyses to estimate the relationship between input cell numbers and final cell number. Results We report in vitro activity data for three drugs (vincristine, melphalan, and etoposide) that are commonly used for pediatric cancer and for the mTOR inhibitor rapamycin, an agent that is currently under preclinical investigation for cancer. To date, the PPTP has completed in vitro testing of 39 investigational and approved agents for single drug activity and two investigational agents in combination with various “standard” chemotherapy drugs. Conclusions This robust in vitro cytotoxicity testing system for pediatric cancers will enable comparisons to response data for novel agents obtained from xenograft studies and from clinical trials. Pediatr Blood Cancer 2011;56:239–249.Keywords
Funding Information
- National Cancer Institute (NO1-CM-42216, CA21765, CA108786, CA82830)
This publication has 48 references indexed in Scilit:
- Initial testing (stage 1) of lapatinib by the pediatric preclinical testing programPediatric Blood & Cancer, 2009
- Initial testing (stage 1) of sunitinib by the pediatric preclinical testing programPediatric Blood & Cancer, 2008
- Initial testing of dasatinib by the pediatric preclinical testing programPediatric Blood & Cancer, 2007
- A fluorescence microplate cytotoxicity assay with a 4-log dynamic range that identifies synergistic drug combinationsMolecular Cancer Therapeutics, 2007
- Credentialing Preclinical Pediatric Xenograft Models Using Gene Expression and Tissue Microarray AnalysisCancer Research, 2007
- Cancer cell line identification by short tandem repeat profiling: power and limitationsThe FASEB Journal, 2004
- Pediatric Cancer Research From Past Successes Through Collaboration to Future Transdisciplinary ResearchJournal of Pediatric Oncology Nursing, 2004
- Molecular cytogenetic characterization of rhabdomyosarcoma cell linesCancer Genetics and Cytogenetics, 2004
- Developmental Therapeutics Program at the NCI: molecular target and drug discovery processLeukemia, 2002
- Insulin-like growth factor I expression by tumors of neuroectodermal origin with the t(11;22) chromosomal translocation. A potential autocrine growth factor.JCI Insight, 1990